{"disease":{"id":"nras-gene-mutation","name":"nras gene mutation"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06270082","title":"Study of IK-595 in RAS- or RAF-altered Advanced Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":75,"lead_sponsor_name":"Ikena Oncology","has_results":false},{"nct_id":"NCT03750175","title":"OPTImal PALliative Anti-epidermal Growth Factor Receptor Treatment in Metastatic Colorectal Cancer -","phase":"","overall_status":"COMPLETED","enrollment_count":49,"lead_sponsor_name":"Karen-Lise Garm Spindler","has_results":false},{"nct_id":"NCT05340621","title":"NAUTILUS: OKI-179 Plus Binimetinib in Patients with Advanced Solid Tumors in the RAS Pathway (Phase 1b) and NRAS-mutated Melanoma (Phase 2)","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":36,"lead_sponsor_name":"OnKure, Inc.","has_results":false},{"nct_id":"NCT04117945","title":"Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":22,"lead_sponsor_name":"Academic and Community Cancer Research United","has_results":true},{"nct_id":"NCT06229340","title":"Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"N.N. Petrov National Medical Research Center of Oncology","has_results":false},{"nct_id":"NCT04566393","title":"Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies","phase":"","overall_status":"AVAILABLE","enrollment_count":null,"lead_sponsor_name":"xCures","has_results":false}],"total":6},"guidelines":[],"source":"Drug Landscape verified database"}